Journals / Göğüs Kalp Damar Anestezi ve Yoğun Bakım Derneği Dergisi / 2022 / Cilt: 28 - Sayı: 2

Jaundice and Its Results After Cardiac Surgery

Kalp Cerrahisi Sonrası Görülen Sarılık ve Sonuçları

Pages
105–112
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, severe persistent hyperbilirubinemia is a condition that needs to be recognized early and precautions should be taken

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Jaundice due to hyperbilirubinemia develops in 10–23% of patients in the early period after cardiac surgery.
📊
Key Findings & Data:Methods: In this retrospective study, patients who underwent cardiac surgery in our clinic between February 2015 and March 2021 were evaluated.
💡
Conclusion & Impact:However, severe persistent hyperbilirubinemia is a condition that needs to be recognized early and precautions should be taken
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Jaundice due to hyperbilirubinemia develops in 10–23% of patients in the early period after cardiac surgery. The aim of our study is to examine the risk factors and clinical consequences of hyperbilirubinemia causing jaundice. Methods: In this retrospective study, patients who underwent cardiac surgery in our clinic between February 2015 and March 2021 were evaluated. Patients who underwent routine or emergency surgery, who developed post-operative jaundice, and whose total bilirubin concentration was >3 mg/dL were included in our study. The baseline demographic data, echocardiography data, laboratory data, operative data, and post-operative status were comprehensively collected. The cutoff value of post-operative total bilirubin was calculated according to hospital mortality in receiver operating characteristic analysis. Results:Total bilirubin concentration was found to be >3 mg/dL in 27 patients. Mean total bilirubin (mg/L) was 9.56±6.427 and median total bilirubin score was 9.02 and the maximum bilirubin concentration was reached at 9.52±8.007 post-operative days. In-hospital mortality occurred in 17 (63.0%) patients. The cutoff for post-operative total bilirubin value was calculated as 9.24 by predicting in-hospital mortality (Sensitivity=70.6%, specificity=90%, and likelihood ratio: 7.05). Conclusion: Patients who develop hyperbilirubinemia in the post-operative period of cardiac surgery should be carefully observed for low cardiac output syndrome, sepsis, or acute liver failure. Low-level hyperbilirubinemia is mostly reversible when cardiac output and oxygen delivery are adequate. However, severe persistent hyperbilirubinemia is a condition that needs to be recognized early and precautions should be taken

Özet

Amaç: Kalp cerrahisi sonrası erken dönemde hiperbilirubinemiye bağlı sarılık hastaların %10 ila %23’ünde gelişir. Çalışmamızın amacı, sarılığa neden olan hiperbilirubineminin risk faktörlerini ve klinik sonuçlarını incelemektir. Yöntem: Bu retrospektif çalışmada, Şubat 2015-Mart 2021 tarihleri arasında kalp cerrahisi geçiren hastalar değerlendirildi. Acil veya elektif cerrahi uygulanıp postoperatif dönemde sarılık gelişen ve total bilirubin konsantrasyonu >3 mg/dL olan hastalar çalışmamıza dahil edildi. Temel demografik, ekokardiyografik, laboratuvar, ameliyat ve ameliyat sonrası veriler kapsamlı bir şekilde toplandı. ROC analiziyle postoperatif total bilirubin cut-off değeri hastane mortalitesine göre hesaplandı. Bulgular: Toplam bilirubin konsantrasyonu 27 hastada >3 mg/dL olarak bulundu. Hastaların ortalama total bilirubin değeri 9,56±6,427 mg/L, medyan toplam bilirubin değeri 9,02 mg/L olarak bulundu. Hastalar maksimum bilirubin konsantrasyonuna ameliyat sonrası 9,52±8,007 günde ulaştı. Hastanede 17 (%63,0) hastada mortalite görüldü. Hastane içi mortaliteyi öngörmek amacıyla hesaplanan postoperatif total bilirubinin cut-off değeri 9,24 mg/L olarak bulundu (duyarlılık= %70,6, özgüllük= %90, olabilirlik oranı=7,05). Sonuç: Kalp cerrahisi sonrası dönemde hiperbilirubinemi gelişen hastalar düşük kalp debisi sendromu, sepsis veya akut karaciğer yetmezliği açısından dikkatle izlenmelidir. Kalp debisi ve oksijen sunumu yeterli olduğunda düşük seviyeli hiperbilirubinemi çoğunlukla geri dönüşümlüdür. Ancak şiddetli persistan hiperbilirubinemi erkenden fark edilmesi ve önlem alınması gereken bir durumdur.

🔖

Cite This Article

TİMUR, B., BAYRAM, M., DUMAN, Z. M., AKSU, T. (2022). Jaundice and Its Results After Cardiac Surgery. Göğüs Kalp Damar Anestezi ve Yoğun Bakım Derneği Dergisi, Cilt: 28 - Sayı: 2, 105–112. https://ajindex.com/articles/525917

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Farag M, Veres G, Szabó G, Ruhparwar A, Karck M, Arif R. Hyperbilirubinaemia after cardiac surgery: The point of no return. ESC Heart Fail 2019;6:694–700
  2. Chen X, Bai M, Zhang W, Sun S, Chen X. The incidence, risk factors, and prognosis of postoperative hyperbilirubinemia after cardiac surgery: A systematic review and meta-analysis. Ann Palliat Med 2021;10:7247–57
  3. Collins JD, Bassendine MF, Ferner R, Blesovsky A, Murray A, Pearson DT, et al. Incidence and prognostic importance of jaundice after cardiopulmonary bypass surgery. Lancet 1983;1:1119–23
  4. Michalopoulos A, Alivizatos P, Geroulanos S. Hepatic dysfunction following cardiac surgery: Determinants and consequences. Hepatogastroenterology 1997;44:779–83
  5. Field E, Horst HM, Rubinfeld IS, Copeland CF, Waheed U, Jordan J, et al. Hyperbilirubinemia: A risk factor for infection in the surgical intensive care unit. Am J Surg 2008;195:304–7
  6. Kavoliuniene A, Vaitiekiene A, Cesnaite G. Congestive hepatopathy and hypoxic hepatitis in heart failure: A cardiologist's point of view. Int J Cardiol 2013;166:554–8
  7. Asano M, Matsumae H, Suzuki K, Nakai Y, Nakayama T, Nomura N, et al. Prognostic risk analyses for postcardiotomy extracorporeal membrane oxygenation in children: A review of early and intermediate outcomes. Pediatr Cardiol 2019;40:89–100
  8. Gottesman LE, Del Vecchio MT, Aronoff SC. Etiologies of conjugated hyperbilirubinemia in infancy: A systematic review of 1692 subjects. BMC Pediatr 2015;15:192
  9. Cui J, Zhao H, Yi B, Zeng J, Lu K, Ma D. Dexmedetomidine attenuates bilirubin-induced lung alveolar epithelial cell death in vitro and in vivo. Crit Care Med 2015;43:e356–68
  10. Nishi H, Sakaguchi T, Miyagawa S, Yoshikawa Y, Fukushima S, Saito S, et al. Frequency, risk factors and prognosis of postoperative hyperbilirubinemia after heart valve surgery. Cardiology 2012;122:12–9
  11. Lyu L, Yao J, Gao G, Long C, Hei F, Ji B, et al. Incidence, risk factors, and outcomes of hyperbilirubinemia in adult cardiac patients supported by veno-arterial ECMO. Artif Organs 2018;42:148–54
  12. Chacon MM, Schulte TE. Liver dysfunction in cardiac surgery - what causes it and is there anything we can do? J Cardiothorac Vasc Anesth 2018;32:1719–21
  13. Poelzl G, Auer J. Cardiohepatic syndrome. Curr Heart Fail Rep 2015;12:68–78
  14. Doctor RB, Dahl RH, Salter KD, Fitz JG. Reorganization of cholangiocyte membrane domains represents an early event in rat liver ischemia. Hepatology 1999;29:1364–74. 15